Atea Pharmaceuticals Inc (NAS:AVIR)
$ 3.7 -0.01 (-0.27%) Market Cap: 311.63 Mil Enterprise Value: -262.81 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 43/100

Atea Pharmaceuticals Inc Bemnifosbuvir Global Phase 3 Registrational Trial - Corporate Call Transcript

Sep 13, 2022 / 12:30PM GMT
Release Date Price: $7.17 (-10.15%)
Operator

Good morning, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Conference Call. (Operator Instructions)

I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Please proceed.

Jonae R. Barnes
Atea Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Good morning, everyone. And welcome to Atea's Pharmaceutical Bemnifosbuvir Clinical Development Program Update Conference Call. Earlier this morning, we issued a press release, which describes our novel global Phase III clinical trial design for bemnifosbuvir.

You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at ir.ateapharma.com in the Events and Presentations section. With me today from Atea is Chief Executive Officer and Founder, Dr. Jean-Pierre Sommadossi; Chief Development Officer, Dr. Janet Hammond; Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran; and our Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot